FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2452-2466 December 7, 2006 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The myeloproliferative disorders comprise several clonal hematologic diseases that are thought to arise from a transformation in a hematopoietic stem cell. The main clinical features of these diseases are the overproduction of mature, functional blood cells and a long clinical course. Chronic myeloid leukemia (not discussed in detail here) is a myeloproliferative disorder that is defined by its causative molecular lesion, the BCR-ABL fusion gene, which most commonly results from the Philadelphia translocation (Ph).¹ The three main Ph-negative myeloproliferative disorders — polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis — are the focus of this article. Less common conditions that are . . . [Full Text of this Article]

Pathogenetic Features

Clues to Molecular Mechanisms

The JAK2 V617F Mutation

Pathophysiological Features

Genetic Marker

Mouse Models

Stem-Cell Biology

Cooperating Mutations

Homozygosity for V617F

Signaling Pathways

Disease Evolution

Molecular Classification

Diagnosis

Treatment

Source Information

From the Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.

Address reprint requests to Dr. Green at the Department of Haematology, Cambridge Institute for Medical Research, Hills Rd., Cambridge CB2 2XY, United Kingdom, or at arg1000@cam.ac.uk.

This article has been cited by other articles:

• Lataillade, J.-J., Pierre-Louis, O., Hasselbalch, H. C., Uzan, G., Jasmin, C., Martyre, M.-C., Le Bousse-Kerdiles, M.-C., on behalf of the French INSERM and the European EU, (2008). Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 112: 3026-3035 [Abstract] [Full Text]  
• Van Pelt, K., Nollet, F., Selleslag, D., Knoops, L., Constantinescu, S. N., Criel, A., Billiet, J. (2008). The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation. Blood 112: 921-922 [Full Text]  
• Bogani, C., Ponziani, V., Guglielmelli, P., Desterke, C., Rosti, V., Bosi, A., Le Bousse-Kerdiles, M.-C., Barosi, G., Vannucchi, A. M., for the Myeloproliferative Disorders Research Cons, (2008). Hypermethylation of CXCR4 Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. Stem Cells 26: 1920-1930 [Abstract] [Full Text]  
• Spivak, J. L., Silver, R. T. (2008). The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 112: 231-239 [Full Text]  
• Gakovic, M., Ragimbeau, J., Francois, V., Constantinescu, S. N., Pellegrini, S. (2008). The Stat3-activating Tyk2 V678F Mutant Does Not Up-regulate Signaling through the Type I Interferon Receptor but Confers Ligand Hypersensitivity to a Homodimeric Receptor. J. Biol. Chem. 283: 18522-18529 [Abstract] [Full Text]  
• Beer, P. A., Campbell, P. J., Scott, L. M., Bench, A. J., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Hasselbalch, H. C., Bowman, R., Wheatley, K., Buck, G., Harrison, C. N., Green, A. R. (2008). MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112: 141-149 [Abstract] [Full Text]  
• Verstovsek, S., Tefferi, A., Cortes, J., O'Brien, S., Garcia-Manero, G., Pardanani, A., Akin, C., Faderl, S., Manshouri, T., Thomas, D., Kantarjian, H. (2008). Phase II Study of Dasatinib in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. Clin. Cancer Res. 14: 3906-3915 [Abstract] [Full Text]  
• Kiladjian, J.-J., Cervantes, F., Leebeek, F. W. G., Marzac, C., Cassinat, B., Chevret, S., Cazals-Hatem, D., Plessier, A., Garcia-Pagan, J.-C., Murad, S. D., Raffa, S., Janssen, H. L. A., Gardin, C., Cereja, S., Tonetti, C., Giraudier, S., Condat, B., Casadevall, N., Fenaux, P., Valla, D. C. (2008). The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111: 4922-4929 [Abstract] [Full Text]  
• Xing, S., Wanting, T. H., Zhao, W., Ma, J., Wang, S., Xu, X., Li, Q., Fu, X., Xu, M., Zhao, Z. J. (2008). Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111: 5109-5117 [Abstract] [Full Text]  
• Bock, O., Hoftmann, J., Theophile, K., Hussein, K., Wiese, B., Schlue, J., Kreipe, H. (2008). Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines. Am. J. Pathol. 172: 951-960 [Abstract] [Full Text]  
• Teofili, L., Foa, R., Giona, F., Larocca, L. M. (2008). Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?. haematol 93: 169-172 [Full Text]  
• Kirsammer, G., Jilani, S., Liu, H., Davis, E., Gurbuxani, S., Le Beau, M. M., Crispino, J. D. (2008). Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 111: 767-775 [Abstract] [Full Text]  
• Wilkins, B. S., Erber, W. N., Bareford, D., Buck, G., Wheatley, K., East, C. L., Paul, B., Harrison, C. N., Green, A. R., Campbell, P. J. (2008). Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 111: 60-70 [Abstract] [Full Text]  
• Gery, S., Gueller, S., Chumakova, K., Kawamata, N., Liu, L., Koeffler, H. P. (2007). Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 110: 3360-3364 [Abstract] [Full Text]  
• Kocher, H M, Mears, L, Lea, N C, Raj, K, Mufti, G J (2007). JAK V617F missense mutation is absent in pancreatic cancer. Gut 56: 1174-1175 [Full Text]  
• Norton, A., Fisher, C., Liu, H., Wen, Q., Mundschau, G., Fuster, J. L., Hasle, H., Zeller, B., Webb, D. K., O'Marcaigh, A., Sorrell, A., Hilden, J., Gamis, A., Crispino, J. D., Vyas, P. (2007). Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood 110: 1077-1079 [Full Text]  
• Passamonti, F., Randi, M. L., Rumi, E., Pungolino, E., Elena, C., Pietra, D., Scapin, M., Arcaini, L., Tezza, F., Moratti, R., Pascutto, C., Fabris, F., Morra, E., Cazzola, M., Lazzarino, M. (2007). Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood 110: 485-489 [Abstract] [Full Text]  
• Finazzi, G., Barbui, T. (2007). How I treat patients with polycythemia vera. Blood 109: 5104-5111 [Abstract] [Full Text]  
• Levitzki, A. (2007). Signal Transduction Therapy of Cancer from Concept to Clinic: Promises and Hurdles. aacredbook 2007: 45-48 [Full Text]  
• Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., Warren, A. J., Gilliland, D. G., Lodish, H. F., Green, A. R. (2007). JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. NEJM 356: 459-468 [Abstract] [Full Text]  
• (2007). JAK2 Mutation Helps Define Polycythemia Vera. JWatch Oncology and Hematology 2007: 4-4 [Full Text]  
• Vannucchi, A. M., Barbui, T. (2007). Thrombocytosis and Thrombosis. ASH Education Book 2007: 363-370 [Abstract] [Full Text]